Jeff Musgnung

1.1k total citations
21 papers, 722 citations indexed

About

Jeff Musgnung is a scholar working on Pharmacology, Experimental and Cognitive Psychology and Psychiatry and Mental health. According to data from OpenAlex, Jeff Musgnung has authored 21 papers receiving a total of 722 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Pharmacology, 8 papers in Experimental and Cognitive Psychology and 7 papers in Psychiatry and Mental health. Recurrent topics in Jeff Musgnung's work include Treatment of Major Depression (16 papers), Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes (8 papers) and Posttraumatic Stress Disorder Research (5 papers). Jeff Musgnung is often cited by papers focused on Treatment of Major Depression (16 papers), Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes (8 papers) and Posttraumatic Stress Disorder Research (5 papers). Jeff Musgnung collaborates with scholars based in United States, United Kingdom and South Africa. Jeff Musgnung's co-authors include I. Benattia, Jonathan Davidson, Dan J. Stein, David S. Baldwin, Barbara O. Rothbaum, Ron Pedersen, Philip T. Ninan, Saeed Ahmed, Susan G. Kornstein and Phebe Tucker and has published in prestigious journals such as Neuropsychopharmacology, The Journal of Clinical Psychiatry and The Journal of Sexual Medicine.

In The Last Decade

Jeff Musgnung

19 papers receiving 662 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jeff Musgnung United States	13	382	296	203	185	102	21	722
Stephanie C. Koke United States	12	289 0.8×	345 1.2×	133 0.7×	183 1.0×	45 0.4×	19	795
Kirsten Rohde United States	7	104 0.3×	215 0.7×	140 0.7×	140 0.8×	153 1.5×	9	611
Nick J. Coupland Canada	10	154 0.4×	173 0.6×	95 0.5×	186 1.0×	116 1.1×	12	580
Taylor Hatchard Canada	13	479 1.3×	209 0.7×	143 0.7×	118 0.6×	139 1.4×	23	840
Atul Khullar Canada	9	319 0.8×	89 0.3×	161 0.8×	116 0.6×	134 1.3×	21	627
A. Tadić Germany	10	145 0.4×	168 0.6×	145 0.7×	185 1.0×	158 1.5×	17	624
Alzbeta Juven‐Wetzler Israel	15	129 0.3×	279 0.9×	67 0.3×	128 0.7×	97 1.0×	23	620
Camilla Bock Denmark	13	122 0.3×	227 0.8×	114 0.6×	193 1.0×	78 0.8×	15	696
S. De Risio Italy	16	157 0.4×	158 0.5×	173 0.9×	137 0.7×	120 1.2×	26	625
Christopher Gross United States	3	119 0.3×	294 1.0×	256 1.3×	50 0.3×	267 2.6×	4	698

Countries citing papers authored by Jeff Musgnung

Since Specialization

Citations

This map shows the geographic impact of Jeff Musgnung's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeff Musgnung with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeff Musgnung more than expected).

Fields of papers citing papers by Jeff Musgnung

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeff Musgnung. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeff Musgnung. The network helps show where Jeff Musgnung may publish in the future.

Co-authorship network of co-authors of Jeff Musgnung

This figure shows the co-authorship network connecting the top 25 collaborators of Jeff Musgnung. A scholar is included among the top collaborators of Jeff Musgnung based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeff Musgnung. Jeff Musgnung is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lobello, Kasia, et al.. (2025). Patient Outcomes With Education, Drug Therapy, and Support: A Study of Venlafaxine ER-Treated Outpatients with Major Depressive Disorder. Psychopharmacology Bulletin. 43(2). 28–44.

Ninan, Philip T., et al.. (2015). Incidence and Timing of Taper/Posttherapy–Emergent Adverse Events Following Discontinuation of Desvenlafaxine 50 mg/d in Patients With Major Depressive Disorder. The Primary Care Companion For CNS Disorders. 17(1). 6 indexed citations

Khan, Arif, et al.. (2014). Abrupt Discontinuation Compared With a 1-Week Taper Regimen in Depressed Outpatients Treated for 24 Weeks With Desvenlafaxine 50 mg/d. Journal of Clinical Psychopharmacology. 34(3). 365–368. 22 indexed citations

Papakostas, George I., Larry Culpepper, Rana Fayyad, Jeff Musgnung, & Christine J. Guico‐Pabia. (2013). Efficacy of desvenlafaxine 50 mg compared with placebo in patients with moderate or severe major depressive disorder. International Clinical Psychopharmacology. 28(6). 312–321. 9 indexed citations

Clayton, Anita H., Susan G. Kornstein, Boadie W. Dunlop, et al.. (2013). Efficacy and Safety of Desvenlafaxine 50 mg/d in a Randomized, Placebo-Controlled Study of Perimenopausal and Postmenopausal Women With Major Depressive Disorder. The Journal of Clinical Psychiatry. 74(10). 1010–1017. 48 indexed citations

Clayton, Anita H., Sujana Reddy, Kristen Focht, Jeff Musgnung, & Rana Fayyad. (2012). An Evaluation of Sexual Functioning in Employed Outpatients with Major Depressive Disorder Treated with Desvenlafaxine 50mg or Placebo. The Journal of Sexual Medicine. 10(3). 768–776. 24 indexed citations

Dunlop, Boadie W., Michael E. Thase, Chuan‐Chuan Wun, et al.. (2012). A Meta-analysis of Factors Impacting Detection of Antidepressant Efficacy in Clinical Trials: The Importance of Academic Sites. Neuropsychopharmacology. 37(13). 2830–2836. 39 indexed citations

Thase, Michael E., Philip T. Ninan, Jeff Musgnung, & Madhukar H. Trivedi. (2011). Remission With Venlafaxine Extended Release or Selective Serotonin Reuptake Inhibitors in Depressed Patients. The Primary Care Companion For CNS Disorders. 13(1). 11 indexed citations

Kornstein, Susan G., Qin Jiang, Sujana Reddy, Jeff Musgnung, & Christine J. Guico‐Pabia. (2010). Short-Term Efficacy and Safety of Desvenlafaxine in a Randomized, Placebo-Controlled Study of Perimenopausal and Postmenopausal Women With Major Depressive Disorder. The Journal of Clinical Psychiatry. 71(8). 1088–1096. 33 indexed citations

10.

Reddy, Sujana, Cecelia P. Kane, B. Pitrosky, et al.. (2009). Clinical utility of desvenlafaxine 50 mg/d for treating MDD: a review of two randomized placebo-controlled trials for the practicing physician. Current Medical Research and Opinion. 26(1). 139–150. 7 indexed citations

11.

Rothbaum, Barbara O., Jonathan Davidson, Dan J. Stein, et al.. (2008). A Pooled Analysis of Gender and Trauma-Type Effects on Responsiveness to Treatment of PTSD With Venlafaxine Extended Release or Placebo. The Journal of Clinical Psychiatry. 69(10). 1529–1539. 19 indexed citations

12.

Davidson, Jonathan, David S. Baldwin, Dan J. Stein, et al.. (2008). Effects of venlafaxine extended release on resilience in posttraumatic stress disorder: an item analysis of the Connor–Davidson Resilience Scale. International Clinical Psychopharmacology. 23(5). 299–303. 36 indexed citations

13.

Stein, Dan J., Ron Pedersen, Barbara O. Rothbaum, et al.. (2008). Onset of activity and time to response on individual CAPS-SX17 items in patients treated for post-traumatic stress disorder with venlafaxine ER: a pooled analysis. The International Journal of Neuropsychopharmacology. 12(1). 23–23. 34 indexed citations

14.

Kocsis, James H., Michael E. Thase, Madhukar H. Trivedi, et al.. (2007). Prevention of Recurrent Episodes of Depression With Venlafaxine ER in a 1-Year Maintenance Phase From the PREVENT Study. The Journal of Clinical Psychiatry. 68(7). 1014–1023. 46 indexed citations

15.

Keller, Martín, Madhukar H. Trivedi, Michael E. Thase, et al.. (2007). The Prevention of Recurrent Episodes of Depression With Venlafaxine for Two Years (PREVENT) Study. The Journal of Clinical Psychiatry. 68(8). 1246–1256. 77 indexed citations

16.

Davidson, Jonathan, David S. Baldwin, Dan J. Stein, et al.. (2006). Treatment of Posttraumatic Stress Disorder With Venlafaxine Extended Release. Archives of General Psychiatry. 63(10). 1158–1158. 148 indexed citations

17.

Keller, Martin B., Bing Chun Yan, James M. Ferguson, et al.. (2006). P.2.c.019 Two-year maintenance treatment study assessing recurrence prevention with venlafaxine XR in patients with recurrent unipolar major depression. European Neuropsychopharmacology. 16. S322–S323. 1 indexed citations

18.

Ahmed, S. F., et al.. (2006). Assessing the Signal Detection Properties of 3 Outcome Scales Used in Clinical Trials of Patients with Generalized Anxiety Disorder. 3(3). 411–411.

19.

Davidson, Jonathan, Barbara O. Rothbaum, Phebe Tucker, et al.. (2006). Venlafaxine Extended Release in Posttraumatic Stress Disorder. Journal of Clinical Psychopharmacology. 26(3). 259–267. 105 indexed citations

20.

Kroenke, Kurt, et al.. (2006). Venlafaxine Extended Release in the Short-Term Treatment of Depressed and Anxious Primary Care Patients With Multisomatoform Disorder. The Journal of Clinical Psychiatry. 67(1). 72–80. 53 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact